Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

被引：3

作者：

Leduc, C. ^{[1
]}

Besse, B. ^{[2
]}

机构：

[1] Strasbourg Univ Hosp, Dept Chest Dis, Strasbourg, France

[2] Gustave Roussy, Dept Canc Med, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷 / 10期

关键词：

D O I：

10.1093/annonc/mdu257

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2092 / 2092

页数：1

共 5 条

[1] 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease [J].

Besse, B. ;

Adjei, A. ;

Baas, P. ;

Meldgaard, P. ;

Nicolson, M. ;

Paz-Ares, L. ;

Reck, M. ;

Smit, E. F. ;

Syrigos, K. ;

Stahel, R. ;

Felip, E. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1475-1484

[2]

Leduc C, 2014, EUR LUNG CANC C 2014

[3] Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC [J].

Ou, S. -H. I. ;

Jaenne, P. A. ;

Bartlett, C. H. ;

Tang, Y. ;

Kim, D. -W. ;

Otterson, G. A. ;

Crino, L. ;

Selaru, P. ;

Cohen, D. P. ;

Clark, J. W. ;

Riely, G. J. .

ANNALS OF ONCOLOGY, 2014, 25 (02) :415-422

[4] Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation [J].

Oxnard, Geoffrey R. ;

Arcila, Maria E. ;

Sima, Camelia S. ;

Riely, Gregory J. ;

Chmielecki, Juliann ;

Kris, Mark G. ;

Pao, William ;

Ladanyi, Marc ;

Miller, Vincent A. .

CLINICAL CANCER RESEARCH, 2011, 17 (06) :1616-1622

[5] Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus [J].

Riely, Gregory J. ;

Kris, Mark G. ;

Zhao, Binsheng ;

Akhurst, Tim ;

Milton, Daniel T. ;

Moore, Erin ;

Tyson, Leslie ;

Pao, William ;

Rizvi, Naiyer A. ;

Schwartz, Lawrence H. ;

Miller, Vincent A. .

CLINICAL CANCER RESEARCH, 2007, 13 (17) :5150-5155

← 1 →